Last reviewed · How we verify
NCT04345536: CovidRegOUH
Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital
trial in COVID-19 in 2,519 participants. Completed in 1 November 2023.
1 January 2022
Quick facts
| Lead sponsor | Oslo University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,519 |
| Start date | 15 March 2020 |
| Primary completion | 1 January 2022 |
| Estimated completion | 1 November 2023 |
| Sites | 1 location across Norway |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Oslo University Hospital
Who can join
Eligibility, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Covid-19 is a recently emerging infectious disease with a very large impact on health care world-wide. The disease is still poorly described. It is an urgent need for better clinical characteristics. A prospective, quality register is therefore established for increasing the knowledge about the disease, the covid patients and the prognosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Predicting severe COVID-19 in the Emergency Department.
Holten AR, Nore KG, Tveiten CEVWK, Olasveengen TM, et al · · 2020 · cited 26× · PMID 33403367 · DOI 10.1016/j.resplu.2020.100042
Verify or expand the search:
- PubMed search for NCT04345536
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Oslo University Hospital trials
Trials by the same sponsor.
- NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
- NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
- NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
- NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
- NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04345536 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
- Last refreshed: 14 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04345536.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing